Expert Outlook: ResMed Through The Eyes Of 9 Analysts
Expert Outlook: ResMed Through The Eyes Of 9 Analysts
專家展望：9位分析師眼中的瑞思邁
Across the recent three months, 9 analysts have shared their insights on ResMed (NYSE:RMD), expressing a variety of opinions spanning from bullish to bearish.
在最近三個月中，9位分析師分享了他們對瑞思邁（紐約證券交易所代碼：RMD）的見解，表達了從看漲到看跌的各種觀點。
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
下表簡要介紹了他們最近的收視率，展示了過去30天中不斷變化的情緒，並將其與前幾個月進行了比較。
Analysts have recently evaluated ResMed and provided 12-month price targets. The average target is $203.22, accompanied by a high estimate of $227.00 and a low estimate of $180.00. This current average reflects an increase of 10.52% from the previous average price target of $183.88.
分析師最近對瑞思邁進行了評估，並提供了12個月的價格目標。平均目標爲203.22美元，最高估計值爲227.00美元，低估值爲180.00美元。目前的平均價格比之前的平均目標價183.88美元增長了10.52％。
Investigating Analyst Ratings: An Elaborate Study
調查分析師評級：一項詳盡的研究
The standing of ResMed among...
通過對分析...
登入免費觀看全文
登入/註冊